Interesting Results of Catalytic Hydrogenation of 3-(2-Nitrophenyl)isoxazoles and 3-(Nitrophenyl)-4,5-dihydroisoxazoles [1]

Abstract

The palladium-on-carbon assisted hydrogenolysis of substituted 3-(2-nitrophenyl)isoxazoles, irrespective of substitution on the isoxazole ring, invariably leads to reduction of the nitro to the amino group with concomitant regiospecific ring closure to yield substituted 4-aminoquinolines. In contrast similar hydrogenation of 3-(2-, 3-, and 4-nitrophenyl)-4,5-dihydroisoxazoles (2-isoxazolines) results in reduction of the nitro group only with conservation of the dihydroisoxazole ring to yield the corresponding 3-(aminophenyl)-4,5-dihydroisoxazoles.

Key words

isoxazole - 4-aminoquinoline - hydrogenation - ring transformation - regiospecific

1

CDRI Communication no 8402. A part of this work was presented as a poster at the CSIR-ACS conference OCCB-2006 at NCL Pune from 7-9^th January, 2006.

References

• 2a Godard A. Queguiner G. J. Heterocycl. Chem.  1980,  17:  465 
• 2b Veronese AC. Callegari SA. Salah SAA. Tetrahedron Lett.  1990,  31:  3485 
• 3 Thomsen I. Torssel KBG. Acta Chem. Scand. B  1988,  42:  309 
• 4 Jensen S. Torssel KBG. Acta Chem. Scand. B  1995,  19:  53 
• 5a Reuben BG. Wittcoff HA. Pharmaceutical Chemicals in Perspective   Wiley; New York: 1989. 
• 5b McIntosh HM. Greenwood BM. Ann. Trop. Med. Parasitol.  1998,  92:  265 
• 5c Deshpande SS. Sheridan RE. Adler M. Toxicon  1997,  35:  433 
• 5d Slater AF. Pharmacol. Ther.  1993,  57:  203 
• 5e O’Neill PM. Willock DJ. Hawley SR. Bray PG. Storr RC. Ward SA. Park BK. J. Med. Chem.  1997,  40:  437 ; and references therein
• 5f Madrid PB. Sherrill J. Liou AP. Weisman JL. DeRisi JL. Guy RK. Bioorg. Med. Chem. Lett.  2005,  15:  1015 
• 6a Andrews IP. Bannister R. Etridge SK. Lewis NJ. Mullane MV. Wells AS. Tetrahedron Lett.  1995,  36:  7743 
• 6b Ife RF. Brown TH. Keeling DJ. Leach CA. Meeson ML. Persons ME. Reavill DR. Theobald CJ. Wiggall KJ. J. Med. Chem.  1992,  35:  3413 
• 7 Moyer MP. Weber FH. Gross JL. Isaac JW. Saint Fort R. Bioorg. Med. Chem. Lett.  1992,  2:  1589 
• 8 Kireev DB. Chretien JR. Raevsky DA. Eur. J. Med. Chem.  1995,  30:  395 
• 9a Marco JL. Carreiras MC. Mini Rev. Med. Chem.  2003,  3:  518 
• 9b Doucet-Personeni C. Bentley PD. Fletcher RJ. Kinkaid A. Kryger G. Pirard B. Taylor A. Taylor R. Taylor J. Viner R. Silman I. Sussman JL. Greenblatt HM. Lewis T. J. Med. Chem.  2001,  44:  3203 
• 9c Han YF. Li CP. Chow E. Wang H. Pang YP. Carlier PR. Bioorg. Med. Chem.  1999,  7:  2569 
• 10 Shinkai H. Ito T. Iida T. Kitao Y. Yamada H. Uchida I. J. Med. Chem.  2000,  43:  4667 
• 11 Medebielle M. Hohn S. Okada E. Myoken H. Shibata D. Tetrahedron Lett.  2005,  46:  7817 
• 12 Roy AK. Batra S. Synthesis  2003,  1347 
• 13 Balsamo A. Coletta I. Guglielmotti A. Landolfi C. Mancini F. Martinelli A. Milanese C. Minutolo F. Nencetti S. Orlandini E. Pinza M. Rapposelli S. Rosello A. Eur. J. Med. Chem.  2003,  38:  157 
• 14a Saxena R. Singh V. Batra S. Tetrahedron  2004,  60:  10311 
• 14b Singh V. Saxena R. Batra S. J. Org. Chem.  2005,  70:  353 
• 14c Roy AK. Pathak R. Yadav GP. Maulik PR. Batra S. Synthesis  2006,  in press 
• 15 Purwono B. Smalley RK. Porter TC. Synlett  1992,  231 
• 16a Kozikowski AP. Stein PD. J. Am. Chem. Soc.  1982,  104:  4023 
• 16b Curran DP. J. Am. Chem. Soc.  1982,  104:  4024 
• 16c Curran DP. J. Am. Chem. Soc.  1983,  105:  4024 
• 16d Auricchio S. Ricca A. Tetrahedron  1987,  43:  3983 
• 17 Quan ML. Ellis CD. He MY. Liauw AY. Lam PYS. Rossi KA. Knabb RM. Luettgen JM. Wright MR. Wong PC. Wexler RR. Bioorg. Med. Chem. Lett.  2003,  13:  1023 
• 18 Vittorio F. Ronsisvalle G. Pappalardo MS. Blandino G. Farmaco  1985,  40:  359 
• 20a Patra A. Batra S. Kundu B. Joshi BS. Roy R. Bhaduri AP. Synthesis  2001,  276 
• 20b Batra S. Roy AK. Patra A. Bhaduri AP. Surin WS. Raghvan SAV. Sharma P. Kapoor K. Dikshit M. Bioorg. Med. Chem.  2004,  12:  2059 
• 21 Srivastava S. Bajpai LK. Batra S. Bhaduri AP. Maikuri JP. Gupta G. Dhar JD. Bioorg. Med. Chem.  1999,  7:  2607 

1

CDRI Communication no 8402. A part of this work was presented as a poster at the CSIR-ACS conference OCCB-2006 at NCL Pune from 7-9^th January, 2006.

19

Crystal data of compound 7d: C₁₀H₉N₃O, M = 187.2; orthorhombic, P2₁2₁2₁, a = 5.710 (1), b = 9.925 (1), c = 16.153 (3) Å, V = 915.4 (3) ų, Z = 4, D _c = 1.358g cm^-3, µ (Mo-Kα) = 0.09 mm^-1, F(000) = 392.0, colorless block, crystal dimensions 0.225 × 0.175 × 0.150 mm, 1370 reflections measured (R _int = 0.019), 1230 unique, R = 0.0456 [(Δ/σ)_max = 000)], wR ₂ = 0.1087 for 1270 on F ² values of reflections with I>2σ(I), S = 1.028 for all data and 128 parameters. Unit cell determination and intensity data collection (2θ = 50°) were performed on a Bruker P4 diffractometer at 293 (2) K. Structure solutions was performed by direct methods and refinements by full-matrix least-squares methods on F ². Programs: XSCANS [Siemens Analytical X-ray Instrument Inc.: Madison, WI, USA, 1996) was used for data collection and data processing], SHELXTL-NT [(Bruker Axs Inc.: Madison, Wisconsin, USA 1997) was used for structure determination, refinements and molecular graphics]. Further details of the crystal structure investigation can be obtained from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK (CCDC deposition no. of compound 7d: 297540.